• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

    13.78 -0.38 (-2.68%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,087,534
    Open 14.15
    Bid (Size) 13.14 (2)
    Ask (Size) 14.00 (5)
    Prev. Close 14.16
    Today's Range 13.69 - 14.24
    52wk Range 10.57 - 33.33
    Shares Outstanding 121,640,069
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    What Happened To Denali Therapeutics Stock Wednesday?
    Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the... 
    Via Benzinga

    Performance

    YTD
    -33.9%
    -33.9%
    1 Month
    +8.2%
    +8.2%
    3 Month
    -36.8%
    -36.8%
    6 Month
    -43.0%
    -43.0%
    1 Year
    -32.8%
    -32.8%

    More News

    Read More
    Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
    Via Benzinga
    Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
    Via Benzinga
    Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
    Via Benzinga
    Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
    Via Investor's Business Daily
    Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
    Via Benzinga
    This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
    Via Benzinga
    Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
    Via Benzinga
    A Biotech Breakout Will Be Led By Small Caps
    Via Talk Markets
    Topics Artificial Intelligence Economy
    Exposures Artificial Intelligence Interest Rates
    Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Via Investor's Business Daily
    3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
    Via InvestorPlace

    Frequently Asked Questions

    Is Denali Therapeutics Inc. - Common Stock publicly traded?
    Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Denali Therapeutics Inc. - Common Stock trade on?
    Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
    The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
    What is the current price of Denali Therapeutics Inc. - Common Stock?
    The current price of Denali Therapeutics Inc. - Common Stock is 13.78
    When was Denali Therapeutics Inc. - Common Stock last traded?
    The last trade of Denali Therapeutics Inc. - Common Stock was at 05/16/25 04:00 PM ET
    What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
    The market capitalization of Denali Therapeutics Inc. - Common Stock is 1.68B
    How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
    Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.